Ekso Bionics Holdings (EKSO) Liabilities and Shareholders Equity (2016 - 2026)
Ekso Bionics Holdings has reported Liabilities and Shareholders Equity over the past 14 years, most recently at $20.1 million for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity fell 24.54% to $20.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $92.2 million, a 17.49% decrease, with the full-year FY2025 number at $20.1 million, down 24.54% from a year prior.
- Liabilities and Shareholders Equity reached $20.1 million in Q4 2025 per EKSO's latest filing, down from $21.7 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $56.5 million in Q1 2021, with the low at $20.1 million in Q4 2025.
- The 5-year median for Liabilities and Shareholders Equity is $32.6 million (2023), against an average of $35.5 million.
- Peak YoY movement for Liabilities and Shareholders Equity: soared 233.47% in 2021, then decreased 29.3% in 2023.
- Tracing EKSO's Liabilities and Shareholders Equity over 5 years: stood at $49.2 million in 2021, then fell by 16.81% to $40.9 million in 2022, then decreased by 29.3% to $28.9 million in 2023, then decreased by 7.84% to $26.7 million in 2024, then fell by 24.54% to $20.1 million in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $20.1 million, $21.7 million, and $23.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.